Technologies for the Development of West Nile Virus Vaccines

References

• Gubler DJ , KunoG , MarkoffL . Flaviviruses . In : Fields Virology (5th Edition).KnipeDM , HowleyPM ( Eds ). Lippincott Williams and Wilkins , Philadelphia, PA, USA , 1155 – 1252 ( 2007 ).
   Google Scholar
• Hayes EB , SejvarJJ , ZakiSR , LanciottiRS , BodeAV , CampbellGL . Virology, pathology, and clinical manifestations of West Nile virus disease . Emerg. Infect. Dis.11 , 1174 – 1179 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Papa A . West Nile virus infections in humans – focus on Greece . J Clin. Virol.58 , 351 – 353 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Murray KO , MertensE , DesprèsP . West Nile virus and its emergence in the United States of America . Vet. Res.41 , 67 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• LaDeau SL , KilpatrickAM , MarraPP . West Nile virus emergence and large-scale declines of North American bird populations . Nature447 , 710 – 713 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lanciotti RS , EbelGD , DeubelVet al. Complete genome sequences and phylogenetic analysis of West Nile virus strains isolated from the United States, Europe, and the Middle East . Virology298 , 96 – 105 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Botha EM , MarkotterW , WolfaardtMet al. Genetic determinants of virulence in pathogenic lineage 2 West Nile virus strains . Emerg. Infect. Dis.14 , 222 – 230 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Papa A , XanthopoulouK , GewehrS , MourelatosS . Detection of West Nile virus lineage 2 in mosquitoes during a human outbreak in Greece . Clin. Microbiol. Infect.17 ( 8 ), 1176 – 1180 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Bakonyi T , FerencziE , ErdélyiKet al. Explosive spread of a neuroinvasive lineage 2 West Nile virus in Central Europe, 2008/2009 . Vet. Microbiol.165 ( 1–2 ), 61 – 70 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Magurano F , RemoliME , BaggieriMet al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy . Clin. Microbiol. Infect.18 , 545 – 547 ( 2012 ).
   Web of Science ®Google Scholar
• Barzon L , PacentiM , FranchinEet al. The complex epidemiological scenario of West Nile virus in Italy . Int. J. Environ. Res. Public Health.10 , 4669 – 4689 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay S , KuhnRJ , RossmannMG . A structural perspective of the flavivirus life cycle . Nat. Rev. Microbiol.3 ( 1 ), 13 – 22 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Chung KM , ThompsonBS , FremontDH , DiamondMS . Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells . J. Virol.81 , 9551 – 9555 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Chung KM , DiamondMS . Defining the levels of secreted non-structural protein NS1 after West Nile virus infection in cell culture and mice . J. Med. Virol.80 ( 3 ), 547 – 556 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Chung KM , NybakkenGE , ThompsonBSet al. Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms . J. Virol.80 , 1340 – 1351 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Chung KM , LiszewskiMK , NybakkenGet al. West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H . Proc. Natl Acad. Sci. USA103 , 19111 – 19116 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Arjona A , LedizetM , AnthonyKet al. West Nile virus envelope protein inhibits dsRNA-induced innate immune responses . J. Immunol.179 , 8403 – 8409 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Laurent-Rolle M , BoerEF , LubickKJet al. The NS5 protein of the virulent West Nile virus NY99 strain is a potent antagonist of type I interferon-mediated JAK-STAT signaling . J. Virol.84 , 3503 – 3515 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Halstead SB , ThomasSJ . Japanese Encephalitis: New Options for Active Immunization . Clin. Infect. Dis.50 , 1155 – 1164 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Ishikawa T , YamanakaA , KonishiE . A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available . Vaccine32 , 1326 – 1337 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Ng T , HathawayD , JenningsN , ChampD , ChiangYW , ChuHJ . Equine vaccine for West Nile virus . Dev. Biol. (Basel)114 , 221 – 227 ( 2003 ).
   PubMedGoogle Scholar
• El Garch H , MinkeJM , RehderJet al. A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse . Vet. Immunol. Immunopathol.123 , 230 – 239 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Gardner IA , WongSJ , FerraroGLet al. Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California . Vet. Res.38 ( 1 ), 109 – 116 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Iyer AV , KousoulasKG . A review of vaccine approaches for West Nile virus . Int. J. Environ. Res. Public Health.10 ( 9 ), 4200 – 4223 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Diamond MS , MehlhopE , OliphantT , SamuelMA . The host immunologic response to West Nile encephalitis virus . Front. Biosci.14 , 3024 – 3034 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Lim SM , KorakaP , OsterhausAD , MartinaBE . West Nile virus: immunity and pathogenesis . Viruses3 ( 6 ), 811 – 828 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Netland J , BevanMJ . CD8 and CD4 T cells in west nile virus immunity and pathogenesis . Viruses5 ( 10 ), 2573 – 2584 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Suthar MS , DiamondMS , GaleMJr . West Nile virus infection and immunity . Nat. Rev. Microbiol.11 ( 2 ), 115 – 128 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Diamond MS , ShresthaB , MarriA , MahanD , EngleM . B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus . J. Virol.77 , 2578 – 2586 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Diamond MS , SitatiEM , FriendLD , HiggsS , ShresthaB , EngleM . A critical role for induced IgM in the protection against West Nile virus infection . J. Exp. Med.198 , 1853 – 1862 ( 2003 ).
   PubMed Web of Science ®Google Scholar
• Oliphant T , EngleM , NybakkenGEet al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus . Nat. Med.11 ( 5 ), 522 – 530 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Beigel JH , NordstromJL , PillemerSRet al. Safety and pharmacokinetics of single intravenous dose of MGAWN1, a novel monoclonal antibody to West Nile virus . Antimicrob. Agents Chemother.54 ( 6 ), 2431 – 2436 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Purtha WE , TedderTF , JohnsonS , BhattacharyaD , DiamondMS . Memory B cells, but not long-lived plasma cells, possess antigen specificities for viral escape mutants . J. Exp. Med.208 ( 13 ), 2599 – 2606 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Mehlhop E , NelsonS , JostCAet al. Complement protein C1q reduces the stoichiometric threshold for antibody-mediated neutralization of West Nile virus . Cell Host Microbe6 ( 4 ), 381 – 391 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Shrestha B , NgT , ChuHJ , NollM , DiamondMS . The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus . Vaccine26 , 2020 – 2033 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Wang T , AndersonJF , MagnarelliLA , WongSJ , KoskiRA , FikrigE . Immunization of mice against West Nile virus with recombinant envelope protein . J. Immunol.167 ( 9 ), 5273 – 5277 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Chabierski S , MakertGR , KerzhnerAet al. Antibody responses in humans infected with newly emerging strains of West Nile Virus in Europe . PLoS ONE8 ( 6 ), e66507 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vázquez S , GuzmánMG , GuillenGet al. Immune response to synthetic peptides of dengue prM protein . Vaccine20 ( 13–14 ), 1823 – 1830 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Beasley DW , BarrettAD . Identification of neutralizing epitopes within structural domain III of the West Nile virus envelope protein . J. Virol.76 , 13097 – 13100 ( 2002 ).
   PubMed Web of Science ®Google Scholar
• Diamond MS , PiersonTC , FremontDH . The structural immunology of antibody protection against West Nile virus . Immunol. Rev.225 , 212 – 225 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Oliphant T , NybakkenGE , AustinSKet al. Induction of epitope-specific neutralizing antibodies against West Nile virus . J. Virol.81 , 11828 – 11839 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Chu JH , ChiangCC , NgML . Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection . J. Immunol.178 ( 5 ), 2699 – 2705 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Martina BE , KorakaP , van den DoelP , van AmerongenG , RimmelzwaanGF , OsterhausAD . Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus . Vaccine26 , 153 – 157 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Throsby M , GeuijenC , GoudsmitJet al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus . J. Virol.80 , 6982 – 6992 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Vogt MR , DowdKA , EngleMet al. Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complementdependent effector mechanisms . J. Virol85 , 11567 – 11580 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ferguson M , WoodDJ , MinorPD . Antigenic structure of poliovirus in inactivated vaccines . J. Gen. Virol . 74 ( 4 ), 685 – 690 ( 1993 ).
   PubMedGoogle Scholar
• Brown F . Review of accidents caused by incomplete inactivation of viruses . Dev. Biol. Stand.81 , 103 – 107 ( 1993 ).
   PubMedGoogle Scholar
• Amanna IJ , RauéHP , SlifkaMK . Development of a new hydrogen peroxide–based vaccine platform . Nat. Med.18 ( 6 ), 974 – 979 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Yamshchikov G , BorisevichV , SereginA . An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development . Virology330 ( 1 ), 304 – 312 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Schlick P , KoflerRM , SchittlBet al. Characterization of West Nile virus live vaccine candidates attenuated by capsid deletion mutations . Vaccine28 , 5903 – 5909 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Widman DG , IshikawaT , GiavedoniLDet al. Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection . Am. J. Trop. Med. Hyg.82 , 1160 – 1167 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Whiteman MC , LiL , WickerJA . Development and characterization of non-glycosylated E and NS1 mutant viruses as a potential candidate vaccine for West Nile virus . Vaccine28 ( 4 ), 1075 – 1083 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Wang T , AndersonJF , MagnarelliLA , WongSJ , KoskiRA , FikrigE . Immunization of Mice Against West Nile Virus with Recombinant Envelope Protein . J. Immunology167 , 5273 – 5277 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• Ledizet M , KarK , FoellmerHGet al. A recombinant envelope protein vaccine against West Nile virus . Vaccine23 , 3915 – 3924 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Lieberman MM , ClementsDE , OgataSet al. Preparation and immunogenic properties of a recombinant West Nile subunit vaccine . Vaccine25 ( 3 ), 414 – 423 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Bonafé N , RiningerJA , ChubetRGet al. A recombinant West Nile virus envelope protein vaccine candidate produced in Spodoptera frugiperda expresSF+ cells . Vaccine27 ( 2 ), 213 – 222 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Watts DM , TeshRB , SiirinMet al. Efficacy and durability of a recombinant subunit West Nile vaccine candidate in protecting hamsters from West Nile encephalitis . Vaccine25 ( 15 ), 2913 – 2918 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lieberman MM , NerurkarVR , LuoHet al. Immunogenicity and protective efficacy of a recombinant subunit West Nile virus vaccine in rhesus monkeys . Clin. Vaccine Immunol.16 ( 9 ), 1332 – 1337 ( 2009 ).
   PubMedGoogle Scholar
• ClinicalTrials.gov . NCT00707642 . http://clinicaltrials.gov/show/NCT00707642 .
   Google Scholar
• Magnusson SE , KarlssonKH , ReimerJMet al. Matrix-M™ adjuvanted envelope protein vaccine protects against lethal lineage 1 and 2 West Nile virus infection in mice . Vaccine32 ( 7 ), 800 – 808 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Reimer JM , KarlssonKH , Lövgren-BengtssonK , MagnussonSE , FuentesA , StertmanL . Matrix-M™ adjuvant induces local recruitment, activation and maturation of central immune cells in absence of antigen . PLoS ONE7 ( 7 ), e41451 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Magnusson SE , ReimerJM , KarlssonKH , LiljaL , BengtssonKL , StertmanL . Immune enhancing properties of the novel Matrix-M™ adjuvant leads to potentiated immune responses to an influenza vaccine in mice . Vaccine31 ( 13 ), 1725 – 1733 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Cox RJ , PedersenG , MadhunASet al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial . Vaccine29 ( 45 ), 8049 – 8059 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Chu JH , ChiangCC , NgML . Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection . J. Immunol.178 ( 5 ), 2699 – 2705 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Zlatkovic J , StiasnyK , HeinzFX . Immunodominance and functional activities of antibody responses to inactivated West Nile virus and recombinant subunit vaccines in mice . J. Virol.85 ( 5 ), 1994 – 2003 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• McDonald WF , HuleattJW , FoellmerHGet al. A West Nile virus recombinant protein vaccine that coactivates innate and adaptive immunity . J. Infect. Dis.195 ( 11 ), 1607 – 1617 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Davis BS , ChangGJ , CroppBet al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays . J. Virol.75 , 4040 – 4047 ( 2001 ).
   PubMed Web of Science ®Google Scholar
• De Filette M , UlbertS , DiamondM , SandersNN . Recent progress in West Nile virus diagnosis and vaccination . Vet. Res.43 , 16 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Martin JE , PiersonTC , HubkaSet al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial . J. Infect. Dis.196 , 1732 – 1740 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE , PiersonTC , HubkaSAet al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial . J. Infect. Dis.203 ( 10 ), 1396 – 1404 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Schneeweiss A , ChabierskiS , SalomoMet al. A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII . Vaccine29 ( 37 ), 6352 – 6357 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Dunn MD , RossiSL , CarterDMet al. Enhancement of anti-DIII antibodies by the C3d derivative P28 results in lower viral titers and augments protection in mice . Virol. J.7 , 95 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Chang DC , LiuWJ , AnrakuIet al. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus . Nat. Biotechnol.26 ( 5 ), 571 – 577 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• Lechardeur D , LukacsGL . Intracellular barriers to non-viral gene transfer . Curr. Gene Ther.2 ( 2 ), 183 – 194 ( 2002 ).
   PubMedGoogle Scholar
• Li L , SaadeF , PetrovskyN . The future of human DNA vaccines . J. Biotechnol.162 ( 2–3 ), 171 – 182 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Suh H , ShinJ , KimYC . Microneedle patches for vaccine delivery . Clin. Exp. Vaccine Res.3 ( 1 ), 42 – 49 ( 2014 ).
   PubMedGoogle Scholar
• De Filette M , SoehleS , UlbertSet al. Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge . PLoS ONE9 ( 2 ), e87837 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Calarota SA , WeinerDB , LoriF , LisziewiczJ . Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine . Vaccine25 ( 16 ), 3070 – 3074 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Lu S . Heterologous prime-boost vaccination . Curr. Opin. Immunol.21 , 346 – 351 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Ishikawa T , TakasakiT , KuraneI , NukuzumaS , KondoT , KonishiE . Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice . Microbes Infect.9 , 1089 – 1095 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Prow TW , ChenX , ProwNAet al. Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice . Small6 ( 16 ), 1776 – 1784 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Guy B , GuirakhooF , BarbanV , HiggsS , MonathTP , LangJ . Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses . Vaccine28 , 632 – 649 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Biedenbender R , BevilacquaJ , GreggAMet al. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults . J. Infect. Dis.203 , 75 – 84 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Brandler S , TangyF . Vaccines in development against West Nile virus . Viruses5 ( 10 ), 2384 – 2409 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Durbin AP , WrightPF , CoxAet al. The live attenuated chimeric vaccine rWN/DEN4d30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers . Vaccine31 ( 48 ), 5772 – 5777 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Brandler S , MarianneauP , LothPet al. Measles vaccine expressing the secreted form of West Nile virus envelope glycoprotein induces protective immunity in squirrel monkeys, a new model of West Nile virus infection . J. Infect. Dis.206 ( 2 ), 212 – 219 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Iyer AV , PaharB , BoudreauxMJet al. Recombinant vesicular stomatitis virus-based west Nile vaccine elicits strong humoral and cellular immune responses and protects mice against lethal challenge with the virulent west Nile virus strain LSU-AR01 . Vaccine27 ( 6 ), 893 – 903 ( 2009 ).
   PubMed Web of Science ®Google Scholar
• Martina BE , van den DoelP , KorakaPet al. A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus . PLoS ONE6 ( 4 ), e18995 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Iglesias MC , FrenkielMP , MollierK , SouqueP , DespresP , CharneauP . A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus . J. Gene. Med.8 ( 3 ), 265 – 274 ( 2006 ).
   PubMed Web of Science ®Google Scholar
• Schepp-Berglind J , LuoM , WandDet al. Complex adenovirus-mediated expression of West Nile virus C, PreM, E, and NS1 proteins induces both humoral and cellular immune responses . Clin. Vaccine Immunol.14 ( 9 ), 1117 – 1126 ( 2007 ).
   PubMedGoogle Scholar
• Lindsey NP , StaplesJE , LehmanJA , FischerM . Centers for Disease Control and Prevention (CDC). Surveillance for human West Nile virus disease - United States, 1999–2008 . MMWR Surveill. Summ.59 ( 2 ), 1 – 17 ( 2010 ).
   PubMedGoogle Scholar
• Boraschi D , Del GiudiceG , DutelC , IvanoffB , RappuoliR , Grubeck-LoebensteinB . Ageing and immunity: addressing immune senescence to ensure healthy ageing . Vaccine28 ( 21 ), 3627 – 3631 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Pinto AK , RichnerJM , PooreEAet al. A hydrogen peroxide-inactivated virus vaccine elicits humoral and cellular immunity and protects against lethal West Nile virus infection in aged mice . J. Virol.87 ( 4 ), 1926 – 1936 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Magurano F , RemoliME , BaggieriMet al. Circulation of West Nile virus lineage 1 and 2 during an outbreak in Italy . Clin. Microbiol. Infect.18 , E545 – 547 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Venter M , van VurenPJ , MentoorJ , PaweskaJ , WilliamsJ . Inactivated West Nile Virus (WNV) vaccine, Duvaxyn WNV, protects against a highly neuroinvasive lineage 2 WNV strain in mice . Vaccine31 ( 37 ), 3856 – 3862 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Minke JM , SigerL , CupillardLet al. Protection provided by a recombinant ALVAC®-WNV vaccine expressing the prM/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain . Vaccine29 ( 28 ), 4608 – 4612 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Erra EO , AsklingHH , YoksanSet al. Cross-protective capacity of Japanese encephalitis (JE) vaccines against circulating heterologous JE virus genotypes . Clin. Infect. Dis.56 , 267 – 270 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention . West Nile virus . http://.cdc.gov/westnile/statsMaps/preliminaryMapsData/histatedate.html .
   Google Scholar
• Dayan GH , PugachevK , BevilacquaJ , LangJ , MonathTP . Preclinical and clinical development of a YFV 17 D-based chimeric vaccine against West Nile virus . Viruses5 ( 12 ), 3048 – 3070 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Vazquez A , Sanchez-SecoMP , RuizSet al. Putative new lineage of west nile virus, Spain . Emerg. Infect. Dis. . 16 , 549 – 552 ( 2010 ).
   PubMed Web of Science ®Google Scholar